106 related articles for article (PubMed ID: 3715796)
1. Thrombosis prophylaxis in an AT III deficient pregnant woman: application of a low molecular weight heparinoid.
Henny CP; ten Cate H; ten Cate JW; Prummel MF; Peters M; Büller HR
Thromb Haemost; 1986 Apr; 55(2):301. PubMed ID: 3715796
[No Abstract] [Full Text] [Related]
2. Pregnancy associated with lupus anticoagulant and heparin induced thrombocytopenia: management with a low molecular weight heparinoid.
van Besien K; Hoffman R; Golichowski A
Thromb Res; 1991 Apr; 62(1-2):23-9. PubMed ID: 1712988
[TBL] [Abstract][Full Text] [Related]
3. In vivo activity of a new heparinoid.
Ockelford PA; Carter CJ; Hirsh J
Pathology; 1985 Jan; 17(1):78-81. PubMed ID: 4000717
[TBL] [Abstract][Full Text] [Related]
4. Treatment of heparin-induced thrombocytopenia with thrombosis by new heparinoid.
Harenberg J; Zimmermann R; Schwarz F; Kübler W
Lancet; 1983 Apr; 1(8331):986-7. PubMed ID: 6132291
[No Abstract] [Full Text] [Related]
5. Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172).
Greinacher A; Eckhardt T; Mussmann J; Mueller-Eckhardt C
Thromb Res; 1993 Jul; 71(2):123-6. PubMed ID: 7689764
[TBL] [Abstract][Full Text] [Related]
6. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study.
Turpie AG; Gent M; Côte R; Levine MN; Ginsberg JS; Powers PJ; Leclerc J; Geerts W; Jay R; Neemeh J
Ann Intern Med; 1992 Sep; 117(5):353-7. PubMed ID: 1503326
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
[No Abstract] [Full Text] [Related]
8. Clinical use of heparin fractions, fragments, and heparinoids.
Messmore HL
Semin Thromb Hemost; 1985 Apr; 11(2):208-12. PubMed ID: 2412297
[No Abstract] [Full Text] [Related]
9. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.
Ortel TL; Gockerman JP; Califf RM; McCann RL; O'Connor CM; Metzler DM; Greenberg CS
Thromb Haemost; 1992 Mar; 67(3):292-6. PubMed ID: 1379384
[TBL] [Abstract][Full Text] [Related]
10. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models.
Meuleman DG
Semin Thromb Hemost; 1989 Oct; 15(4):370-2. PubMed ID: 2479103
[TBL] [Abstract][Full Text] [Related]
11. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172).
Magnani HN
Thromb Haemost; 1993 Oct; 70(4):554-61. PubMed ID: 7509508
[TBL] [Abstract][Full Text] [Related]
12. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin.
Hoppensteadt D; Racanelli A; Walenga JM; Fareed J
Semin Thromb Hemost; 1989 Oct; 15(4):378-85. PubMed ID: 2530633
[No Abstract] [Full Text] [Related]
13. Safe anticoagulation with danaparoid in pregnancy and lactation.
Schindewolf M; Mosch G; Bauersachs RM; Lindhoff-Last E
Thromb Haemost; 2004 Jul; 92(1):211. PubMed ID: 15213864
[No Abstract] [Full Text] [Related]
14. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
Vogel GM; van Amsterdam RG; Kop WJ; Meuleman DG
Thromb Haemost; 1993 Jan; 69(1):29-34. PubMed ID: 8446935
[TBL] [Abstract][Full Text] [Related]
15. Heparin-associated thrombocytopenia type II in a patient with end-stage renal disease: successful anticoagulation with the low-molecular-weight heparinoid Org 10172 during haemodialysis.
Greinacher A; Philippen KH; Kemkes-Matthes B; Möckl M; Mueller-Eckhardt C; Schaefer K
Nephrol Dial Transplant; 1993; 8(10):1176-7. PubMed ID: 7505906
[No Abstract] [Full Text] [Related]
16. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke.
Turpie AG; Levine MN; Hirsh J; Carter CJ; Jay RM; Powers PJ; Andrew M; Magnani HN; Hull RD; Gent M
Lancet; 1987 Mar; 1(8532):523-6. PubMed ID: 2434815
[TBL] [Abstract][Full Text] [Related]
17. Use of Org 10,172 in the treatment of heparin-induced thrombocytopenia and thrombosis.
Kiers L; Grigg LE; Cade JF; Street PR; Chong BH
Aust N Z J Med; 1986 Oct; 16(5):719. PubMed ID: 3469977
[No Abstract] [Full Text] [Related]
18. Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease.
Ten Cate H; Henny CP; Büller HR; Ten Cate JW; Magnani HN
Ann Neurol; 1984 Mar; 15(3):268-70. PubMed ID: 6721448
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial.
Gerhart TN; Yett HS; Robertson LK; Lee MA; Smith M; Salzman EW
J Bone Joint Surg Am; 1991 Apr; 73(4):494-502. PubMed ID: 1707413
[TBL] [Abstract][Full Text] [Related]
20. Successful use of heparinoids in a pregnancy complicated by allergy to heparin.
Taylor AA
BJOG; 2001 Sep; 108(9):1011-2. PubMed ID: 11563455
[No Abstract] [Full Text] [Related]
[Next] [New Search]
